An interventional study of Vitamin D3 and placebo in Vitamin D Deficiency, sponsored by Winthrop University Hospital. Terminated at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-07-03.
Sponsored by Winthrop University Hospital · Not applicable, Interventional, and Treatment
Vitamin D deficiency is common in obese patients. Most of vitamin D supplementation studies were done with non-obese subjects. This study looks at vitamin D supplementation requirements in obese patients as compared to non-obese subjects. This study also looks at changes in vitamin D level in obese patients undergoing medical weight loss. It is thought that obese patients have vitamin D deficiency through storage of vitamin D in the fat compartment not readily available for blood measurement. The investigators' hypothesis is that with medical weight loss vitamin D levels will increase in obese subjects.
We intend to study changes in serum 25(OH)D level with calorie restricted weight loss in obese subjects. This will be a double dummy, placebo controlled randomized trial. Subjects whose serum 25(OH)D level is below 80 nmol/L will be assigned randomly to either the vitamin D supplemented or the placebo group. Those who are assigned to the placebo group will be weighed on a weekly basis and serum 25(OH)D level will be followed every 8 weeks for a minimum of 16 weeks and extended to the duration of weight loss along with serum calcium level. Changes in serum 25(OH)D level will be obtained with weight loss through restricted caloric intake.
To study the 25(OH)D dose-response curve with vitamin D supplementation in obese subjects, vitamin D supplemented group will receive initial daily vitamin D3 supplementation dose based on their baseline serum 25(OH)D level as described in Methods and Procedures section. Serum 25(OH)D levels will be drawn at 8 weeks and adjustments to the dose will be made based on the an algorithm to achieve serum 25(OH)D levels between 80 and 140 nmol/L. The dose-response curve obtained at 8 weeks will be compared to the one already established with non-obese subjects. Serum 25(OH)D level will be obtained at 16 weeks and compared with the data available from non-obese subjects.
Exclusion Criteria:
Half of subjects will be randomized to the placebo group.
Drug: placebo
This is the study group that receives Vitamin D supplementation.
Drug: Vitamin D3
Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
Mean Level of 25(OH)D
Vitamin D (25(OH)D) level at Baseline.
Time frame: Baseline
Mean Level of 25(OH)D
Vitamin D (25(OH)D) level at Month 2.
Time frame: Week 8
Volunteers were recruited during the winter months from areas in a surrounding Long Island, New York by advertisement through flyers and direct mail. Volunteers were 18-65 years old with a BMI of \>35kg/m2. Recruitment began in January of 2009 at the Bone Mineral Research Center at Winthrop University Hospital
| Milestone | Placebo | Vitamin D3 |
|---|---|---|
| Started | 13 | 14 |
| Completed | 13 | 14 |
| Not completed | 0 | 0 |
Vitamin D (25(OH)D) level at Baseline.
| nmol/L | Placebo | Vitamin D |
|---|---|---|
| Mean Level of 25(OH)D | 51.1 ± 13.9 | 49.2 ± 15.3 |
Vitamin D (25(OH)D) level at Month 2.
| nmol/L | Placebo | Vitamin D |
|---|---|---|
| Mean Level of 25(OH)D | 49.9 ± 17.9 | 74.5 ± 13.43 |
Collected over Adverse events were collected from the date the patient started the study medications until the date they completed the study, typically 2 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/13 (0%) | 0/13 (0%) |
| Vitamin D3 | — | 0/14 (0%) | 0/14 (0%) |
| Age, Continuous(years) | Placebo | Vitamin D3 | Total |
|---|---|---|---|
| Mean | 55.8 ± 7.43 | 53.5 ± 12.5 | 54.8 ± 9.83 |
| Age, Customized(participants) | Placebo | Vitamin D3 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 14 | 27 |
| >=65 years | 0 | 0 | 0 |
| Sex/Gender, Customized(participants) | Placebo | Vitamin D3 | Total |
|---|---|---|---|
| Female | 5 | 8 | 13 |
| Male | 8 | 6 | 14 |
| Region of Enrollment(participants) | Placebo | Vitamin D3 | Total |
|---|---|---|---|
| United States | 13 | 14 | 27 |
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Winthrop University Hospital